Equations are not being displayed properly on some articles. We hope to have this fixed soon. Our apologies.

Howes M.D., PhD., R. (2007). Cancer, Apoptosis and Reactive Oxygen Species: A New Paradigm. PHILICA.COM Article number 86.

ISSN 1751-3030  
Log in  
Register  
  1208 Articles and Observations available | Content last updated 22 October, 12:04  
Philica entries accessed 3 371 105 times  


NEWS: The SOAP Project, in collaboration with CERN, are conducting a survey on open-access publishing. Please take a moment to give them your views

Submit an Article or Observation

We aim to suit all browsers, but recommend Firefox particularly:

Cancer, Apoptosis and Reactive Oxygen Species: A New Paradigm

Randolph Michael Howes M.D., PhD.confirmed user (Plastic surgery, Johns Hopkins Hospital, Baltimore)

Published in medi.philica.com

Abstract
Apoptosis or cellular suicide is one of the most important means of eliminating precancerous and cancerous cells from the body. Cellular apoptotic execution is usually modulated by levels of electronically modified oxygen derivatives serving as the effector stimulus initiating subsequent cellular death. Studies have shown that antioxidants can block apoptosis in many tumorous or neoplastic cell types. Caution should be exercised to prevent creating insufficient electronically modified oxygen derivative (EMOD) levels and to avoid the injudicious use of antioxidants, especially in subjects with compromised immunity or with cancerous or precancerous conditions. Allowance of cellular proliferation may represent an EMOD insufficiency state and an EMOD insufficiency syndrome may explain clustering of common diseases, such as cancer, atherosclerosis, diabetes and obesity. In short, sufficient prooxidant levels can induce cancer cell apoptosis, which can be blocked or nullified by certain antioxidants.

Article body


 Introduction

An accumulating body of evidence favors the involvement of intracellular reactive oxygen species at some point during apoptotic execution. 1-5

The critical role of cellular redox status in the regulation of death signaling has been demonstrated. 6-9 Investigators have shown that intracellular increase in H2O2 was a critical effector mechanism during drug-induced apoptosis of human tumor cells. 4 This increase in H2O2 was responsible for early cytosolic acidification, thus creating an environment conducive for caspase activation.

Most of the past studies seem to imply that the mitochondrial burst of H2O2 is likely to be a downstream effector mechanism for the execution signal.  Hydrogen peroxide (H2O2) is considered to be a mediator of most forms of apoptotic cell death. 5

Many investigators have demonstrated the critical role of intracellular H2O2 in rendering the cytosolic milieu permissive for efficient apoptotic execution. 4, 5, 10 I believe that this strongly indicates that H2O2 is one of the essential agents for cellular killing.

Tumor cell hypoxia

Otto Warburg was the first scientist to implicate ground state oxygen in cancer, 11 although he was later derided for it. It appears that EMODs, not ground state oxygen, are primary effectors for modulation of cellular apoptosis.

A pro-oxidant intracellular milieu is an invariable finding in cancer cells and has been shown to endow cancer cells with a survival advantage over their normal counterparts. 12, 13 However, I believe that it is this very feature which allows us to have selectivity for cancer cell killing.

Most human tumors develop regions of chronically or transiently hypoxic cells during growth. 14 Clinical studies have shown that metastatic spread is associated with hypoxia in the primary tumor. 15, 16

Hypoxia (oxygen tension [pO2] value 10 mmHg) is associated with lower overall and disease-free survival, greater recurrence, and less locoregional control in head and neck carcinoma, cervical carcinoma and soft-tissue sarcoma. Tumor hypoxia is associated with adverse clinical outcomes and reduced patient survival. Tumor hypoxia is a therapeutic concern since it can reduce the effectiveness of radiotherapy, some O2-dependent cytotoxic agents, and photodynamic therapy. 17

EMODs

Both radiotherapy and photodynamic therapy generate electronically modified oxygen derivatives (EMODs) within treated carcinoma cells and they are felt to be essential for induction of apoptosis of the neoplastic cells. At least 127 genes and signal transducing proteins have been reported to be sensitive to reductive and oxidative (redox) states in the cell. 18

Evidence from both animal and human studies indicates that exercise may reduce the risk of breast cancer.  Among eleven human studies that took into account many of the established risk factors for breast cancer, eight reported a decrease in the risk of breast cancer in pre-menopausal, post-menopausal or all women with high levels of physical activity compared to women with low levels of activity. 19 With exercise, there is a consequent increase in oxygen consumption of up to 10 to 15 fold and a concomitant increase in EMOD production.

The chemotherapeutic agents doxorubicin, mitomycin C, etoposide and cisplatin are superoxide generating agents 20.  The anti-estrogen tamoxifen, increasingly used alongside other breast cancer therapies, has also been shown to induce oxidative stress and increased apoptotic-inducing EMOD levels within carcinoma cells in vitro. 21

Testosterone deficiency, through castration, increases EMODs and this is the best treatment for prostate cancer, which has resulted in cases of long term total remission of the cancer. Administration of testosterone to the castrated group resulted in decreases in EMODs, which would "allow" for continued growth of prostate cancer.  Additionally, antioxidant enzymes are restored by testosterone administration, which would result in a further deficiency state of EMODs and a more favorable environment for cancer survival and growth. 22

When normal androgenic status is disrupted, such as under the condition of castration-induced deprivation, EMODs are increased in the prostate via up-regulation of Nox-dependent EMOD anabolism and down-regulation of a number of key antioxidant enzyme EMOD scavengers.  All of these factors help to increase EMODs, which will aid in controlling neoplastic growth, and thus, it has been found that castration is the best treatment for prostatic cancer.  This data strongly supports my Unified theory, which states that EMODs are normally of low toxicity and are essential secondary cellular messengers.

This data may relate to the results from the Finasteride Prostate Cancer Prevention Trial, which demonstrated that androgen-blockade at the cellular level lowers prostate cancer risk but increases the prevalence of high-grade cancers. 23

Many human cancer cells overproduce hydrogen peroxide.  High levels (up to 0.5 nmol/hr/104 cells) of hydrogen peroxide are constitutively released from a wide range of human tumor cells.  I believe that this makes the tumor cell more vulnerable to increases in EMODs and creates selectivity for PDT and cancer therapy. In other words, adding a specified amount of EMODs to neoplastic and normal cells can induce apoptosis in a cancer cell and not do so in a normal cell. This establishes a unique therapeutic site for selectivity in the killing of tumorous cells, without doing harm to normal cells.

On September 12, 2005, Mark Levine's group published online for PNAS results showing that, "Pharmacologic ascorbic acid concentrations selectively kill cancer cells: Action as a pro-drug to deliver hydrogen peroxide to tissues." 24

Dehydroascorbic acid (DHA) may be the key to vitamin C therapy. Dr. Benade et al. at the National Cancer Institute found that in cultures vitamin C selectively destroyed cancer cells by generating excess intracellular H2O2.  25 Ascorbic acid and ascorbic acid salts are preferentially toxic to tumor cells, which are thought to be related to intracellular generation of hydrogen peroxide. 26, 27

I believe that the cancer cells have higher levels of EMODs, due to low levels of antioxidants and antioxidant enzymes, and it therefore takes a smaller amount of additional EMODs to reach apoptotic levels than for normal cells to reach apoptotic levels.  This may be the trigger point of selectivity for toxicity to cancer cells without harming normal cells.

Myeloperoxidase (MPO) deficiency

EMOD insufficiency levels appear to be related to increased risk of neoplasia.

Myeloperoxidase is a heme-containing enzyme that catalyzes the reaction between hydrogen peroxide and chloride ions, producing hypochlorite or hypochlorous acid (HOCl), a potent oxidation agent. 28 Evidence from a number of investigators indicates that individuals with total MPO deficiency show a high incidence of malignant tumors. 29

There appears to be a high incidence of malignancy in patients with complete MPO deficiency, suggesting a relationship between a defective MPO system and neutrophil-mediated tumor cell cytotoxicity. 30 Patients with cancer of the larynx show a deficiency of neutrophil myeloperoxidase. Activity of myeloperoxidase in neutrophils from patients with gastric carcinoma is slightly elevated. 31

Decreased MPO activity in PMN from acute myeloid leukemia (AML) patients may contribute to the increased susceptibility to infections and that in the pre-remission phase of the disease it may account for approximately 15% of the infections. 32

A complete lack of myeloperoxidase (MPO) was demonstrated in a boy suffering from acute myeloid leukemia during the acute phase of the disease and after a remission was achieved. This indicates a possible connection between MPO deficiency and leukemia. 33 Also, mice deficient in myeloperoxidase have somewhat increased atherosclerosis. 34  I believe that this follows the pattern of disease clustering in the EMOD insufficiency syndrome.

Antioxidants

EMOD insufficiency levels, secondary to antioxidants, also appear to be related to increased risk of neoplasia.

A study on human gliomas cells demonstrated that overexpression of CuZnSOD can inhibit tumor cell growth. 35 Again, H2O2 may be generated to sufficiently high levels such that it demonstrates antineoplastic properties, in accordance with my Unified theory. To the contrary, in tumor cells, the activity of CuZnSOD is usually low. 36

Catalase deficiency in humans was first documented by Dr. Takahara in 1946. 37 Japanese acatalasemic patients are phenotypically normal with the exception of an increased tendency in development of progressive oral gangrene, presumably as a result of tissue damage from H2O2 produced by peroxide-generating bacteria such as streptococci and pneumococci as well as by the phagocytic cells at the sites of bacterial infection. 38

Mice null for the Gpx1 and Gpx2 genes appear normal under normal housing conditions, although they tend to be more sensitive to oxidative stress. More recently, knockout mice for catalase were generated, and these mice null for catalase appear normal as well. 39 Animals null for CAT and Gpx1 and Gpx2 develop normally. 40 This argues strongly for the low toxicity of EMODs, which is an integral part of my Unified Theory (available at www.thepundit.com). 43, 44

I believe that it is of utmost importance to consider the fact that animals null for CAT and Gpx1 and Gpx2 appear to develop normally and live normal lives.  This must weaken the argument that EMODs are extremely toxic and causative of up to 100 pathophysiologies.

The results show that (1) the increased liver antioxidant capacity of CAT and Gpx in male mice might be a sign of oxidative stress; (2) the increase in CAT and Gpx activities in male mice is strongly correlated with incidence of hepatic tumors; (3) the significantly increased SOD activity in tumor-bearing mice might have induced damage with accumulated hydrogen peroxide. 41

The free radical theory

Denham Harman 42 proposed in 1956 the "free radical theory," speculating that damage to aerobic organisms occurs due to harmful free radical production of oxidative products. Subsequently, these alleged damaging derivatives of oxygen, which were termed either oxygen free radicals or "reactive oxygen species (ROS)", were defined as being deleterious and harmful. For greater accuracy, I will use the term "electronically modified oxygen derivatives (EMODs)" to replace the less accurate term of reactive oxygen species.

Unfortunately, the overly optimistic predictions based on the free radical theory have repeatedly failed to scientifically support the free radical theory. 43-47 The Harvard School of Public Health web site summed it up this way, "The evidence accumulated thus far on antioxidant vitamins isn't promising. Randomized trials of vitamin C, vitamin E, and beta-carotene haven't revealed much in the way of protection from heart disease, cancer, or aging-related eye diseases (website accessed 2/09/06). I present in great detail the essential task of EMODs for the normal functioning of aerobic cells and their crucial role as secondary cellular messengers in my e-books, 43-47 which are available in "The Howes Selective World Library of Oxygen Metabolism at www.thepundit.com.

The free radical theory erroneously stated that diseases and the aging process resulted from the "stochastic" accumulation of oxidative damage purportedly caused by EMODs, from sources such as the environment and from normal by-products of cellular metabolism. 48-50 Contrary to the free radical theory of aging, which argues that EMODs are uncontrolled, EMODs are under strict metabolic control. There is a compartmentalization of oxidative events, which strongly suggests EMODs' crucial role influencing and modulating physiological stimuli, signaling mechanisms, and functional homeostasis. 51, 52 

Tests of effect of vitamin E and other antioxidant vitamins or their combinations on clinical manifestations of cardiovascular disease, cancer and diabetes, have consistently shown that commonly used antioxidant vitamin regimens (vitamins E, C, beta carotene, or a combination thereof) do not significantly reduce overall cardiovascular events, diabetes or cancer in studies such as HOPE, 53 GISSI, 54 ATBC, 55 Hennekens study, 56 Omenn's study, 57 Brown's study, 58 MRC/BHF, 59 Vivekananthan's meta-study, 60 Miller's meta-study. 61 Antioxidants actually appear to cause harm and in some studies they may increase overall mortality, which is discussed in a 2005 nutrition and supplement review in JAMA. 62 Yet, one should keep in mind the fact that certain vitamin supplements may be beneficial for some people, such as those with a deficiency state, pregnant women, women of childbearing age, and people with restricted dietary intakes.

Apoptosis is a form of cell death necessary to make way for new cells and to remove cells in which the DNA has been damaged to the point of cancerous change. Thus, it is believed that one of the most important functions of apoptosis is the elimination of preneoplastic and neoplastic cells. 63 In most forms of cellular suicide, the signaling cascade requires EMODs as essential intermediate messenger molecules. 64

Inhibition of apoptosis by antioxidants may explain why, in several studies in heavy smokers, vitamin E and β-carotene enhanced carcinogenesis in the lung. 65 Increased formation of EMODs also accompanies apoptosis induced by most, if not all, other stimuli, 66 and free radical scavengers often nearly always delay such apoptosis. 67-76

Davies 77 has shown that cellular division or cell death is EMOD concentration dependent, when utilizing the EMOD, H2O2. Cellular responses go from proliferation, to arrest, to apoptosis.

Conclusion

The primary means that the human body has to rid itself of precancerous and cancerous cells is by electronically modified oxygen derivative-induced apoptosis.  This crucial process can be blocked or negated by either small molecule antioxidants or by antioxidant enzymes.  Cellular proliferation, cellular arrest and cellular suicide appear to be modulated by relative concentrations of electronically modified oxygen derivatives. Cautious use of antioxidants may be appropriate for individuals with tumorous or preneoplastic growths. EMODs appear to be gaining an increasingly important role in the modulation of cellular proliferation and cellular death. EMODs offer a therapeutic site in the selective killing of neoplastic cells, without causing harm to normal cells. Indeed, the potential of therapeutically increasing EMOD levels in combating disease offers the possibility of a promising opportunity.

 

References

 

  • 1. Fleury C, Mignotte B, Vayssiere JL Mitochondrial reactive oxygen species in cell death signaling. Biochimie 2002; 84:131-41.
  • 2. Mansat-de Mas V, Bezombes C, Quilletary A, et al Implication of radical oxygen species in ceramide generation, c-Jun N-terminal kinase activation and apoptosis induced by daunorubicin. Mol Pharmacol 1999;56:867-74.
  • 3. Simizu S, Umezawa K, Takada M, Arber N, Imoto M Induction of hydrogen peroxide production and Bax expression by caspase-3(-like) proteases in tyrosine kinase inhibitor-induced apoptosis in human small cell lung carcinoma cells. Exp Cell Res 1998;238:197-203.
  • 4. Hirpara JL, Clement MV, Pervaiz S Intracellular acidification triggered by mitochondrial-derived hydrogen peroxide is an effector mechanism for drug-induced apoptosis in tumor cells. J Biol Chem 2001;276:514-521.
  • 5. Clement MV, Ponton A, Pervaiz S Apoptosis induced by hydrogen peroxide is mediated by decreased superoxide anion concentration and reduction of intracellular milieu. FEBS Lett 1998; 440:13-18.
  • 6. Clement M. V., Pervaiz S. Reactive oxygen intermediates regulate cellular response to apoptotic stimuli: an hypothesis. Free Radic. Res., 30: 247-252, 1999.
  • 7. Clement M. V., Pervaiz S. Intracellular superoxide and hydrogen peroxide concentrations: a critical balance that determines survival or death. Redox. Rep., 6: 211-214, 2001.
  • 8. Pervaiz S., Clement M. V. Hydrogen peroxide-induced apoptosis: oxidative or reductive stress?. Methods Enzymol., 352: 150-159, 2002.
  • 9. Pervaiz S., Clement M. V. A permissive apoptotic environment: function of a decrease in intracellular superoxide anion and cytosolic acidification. Biochem. Biophys. Res. Commun., 290: 1145-1150, 2002.
  • 10. Hampton M. B., Orrenius S. Dual regulation of caspase activity by hydrogen peroxide: implications for apoptosis. FEBS Lett., 414: 552-556, 1997.
  • 11. Warburg, O. On the origin of cancer cells. Science 1956; 123: 309-314.
  • 12. Cerutti P. A. Prooxidant states and tumor promotion. Science (Wash. DC), 227: 375-381, 1985.
  • 13. Burdon R. H., Gill V., Rice-Evans C. Oxidative stress and tumour cell proliferation. Free Radic. Res. Commun., 11: 65-76, 1990.
  • 14. Vaupel P., Kallinowski F., Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res., 49: 6449-6465, 1989.
  • 15. E. K. Rofstad, H. Rasmussen, K. Galappathi, B. Mathiesen, K. Nilsen and B.A. Graff. Hypoxia Promotes Lymph Node Metastasis in Human Melanoma Xenografts by Up-Regulating the Urokinase-Type Plasminogen Activator Receptor. Cancer Research 62, 1847-1853, March 15, 2002.
  • 16. Peter Vaupel. Tumor Hypoxia: Definitions and Current Clinical, Biologic, and Molecular Aspects. Michael Höckel, Journal of the National Cancer Institute, Vol. 93, No. 4, 266-276, February 21, 2001.
  • 17. P. Vaupel and L. Harrison. Tumor Hypoxia: Causative Factors, Compensatory Mechanisms, and Cellular Response. Oncologist, November1,2004; 9(suppl_5): 4 - 9.
  • 18. Allen, R.G. and Tresini, M. Oxidative stress and gene regulation. Free Rad Biol Med 2000; 28: 463-499.
  • 19. Cornell University Program on Breast Cancer and Environmental risk Factors. January 1999, Fact Sheet #19.
  • 20. Yokomizo A, Ono M, Nanri H, Makino Y, Ohga T, Wada M, Okamoto T, Yodoi J, Kuwano M, Kohno K. Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide. Cancer Res 1995;55:4293-4296.
  • 21. Ferlini C, Scambia G, Marone M, Distefano M, Gaggini C, Ferrandina G, Fattorossi A, Isola G, Benedetti Panici P, Mancuso S. Tamoxifen induces oxidative stress and apoptosis in estrogen receptor-negative human cancer cell lines. Br J Cancer 1999;79:257-263.
  • 22. Tam NN, Gao Y, Leung YK, Ho SM. Androgenic regulation of oxidative stress in the rat prostate: involvement of NAD(P)H oxidases and antioxidant defense machinery during prostatic involution and regrowth. Am J Pathol. 2003 Dec;163(6):2513-22.
  • 23. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA, Jr: The influence of finasteride on the development of prostate cancer. N Engl J Med 2003, 349:215-224.
  • 24. Q. Chen,M. G. Espey, M. C. Krishna, J. B. Mitchell, C.P. Corpe G. R. Buettner, E. Shacter, and M. Levine. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: Action as a pro-drug to deliver hydrogen peroxide to tissues. PNAS. September 20, 2005. Vol. 102. No. 38. pp. 13604-13609.
  • 25. Benade L, Howard T and Burke D. Synergistic killings of Ehrlich ascites carcinoma cells by ascorbate and 3 amino-1, 2, 4-triazole. Oncology. 1969;23:33-43.
  • 26. Tsao C, Dungham B and Ping Y. In vivo antineoplastic activity of ascorbic acid for human mammary tumour. In vivo. 2: 147-50. 1988.
  • 27. Bram S et al. Vitamin C preferential toxicity for malignant melanoma cells. Nature. 284: 629-31. 1980.
  • 28. Oredson S, Ovarfordt P, Plate G. Polymorphonuclear leucocytes increase reperfusion injury in skeletal muscle. Int Angiol 1995;14:80-8.
  • 29. Lanza F. Clinical manifestation of myeloperoxidase deficiency. J Mol Med. 1998 Sep;76(10):676-81.
  • 30. Lanza F, Fietta A, Spisani S, Castoldi GL, Traniello S. Does a relationship exist between neutrophil myeloperoxidase deficiency and the occurrence of neoplasms? J Clin Lab Immunol. 1987 Apr;22(4):175-80.
  • 31. Gierek T, Lisiewicz J, Moszczynski P, Pilch J, Namyslowski G. Enzymatic deficiencies of the immune system cells in patients with cancer of the larynx and other malignancies. Auris Nasus Larynx. 1985;12(1):47-51.
  • 32. Nielsen HK, Bendix-Hansen K. Myeloperoxidase-deficient polymorphonuclear leucocytes (III): Relation to incidence of infection in acute myeloid leukaemia. Scand J Haematol. 1984 Jul;33(1):75-9.
  • 33. Hunh D, Belohradsky BH, Haas R. Familial peroxidase-deficiency and acute myeloid leukemia (author's transl) Acta Haematol. 1978;59(3):129-43.
  • 34. Brennan ML, Anderson MM, Shih DM, Qu XD, Wang X, Mehta AC, Lim LL, Shi W, Hazen SL, Jacob JS, Crowley JR, Heinecke JW, and Lusis AJ. Increased atherosclerosis in myeloperoxidase-deficient mice. J Clin Invest 107: 419-430, 2001.
  • 35. Zhang Y, Zhao WL, Zhang HJ, Doman FE, Oberley LW. (2002) Overexpression of copper zinc superoxide dismutase suppresses human glioma cell growth. Cancer Res. 62:1205-1212.
  • 36. Oberley LW. (2001) Anticancer therapy by overexpression of superoxide dismutase. Antioxid Redox Signal. 3:46-472.
  • 37. Takahara, S., and Miyamoto, H. (1948) Jpn. J. Otol. 51, 163-164.
  • 38. Eaton, J. W., and Ma, M. (1995) in The Metabolic and Molecular Bases of Inherited Disease (Scriver, C. R., Beaudet, A. L., Sly, W. S., and Valle, D., eds) pp. 2371-2383, McGraw-Hill Inc., New York.
  • 39. Ho, Y. S., Xiong, Y., Ma, W., Spector, A., and Ho, D. S. (2004) J. Biol. Chem. 279, 32804-32812.
  • 40. Eaton, J. W., and Ma, M. (1995) in The Metabolic and Molecular Bases of Inherited Disease (Scriver, C. R., Beaudet, A. L., Sly, W. S., and Valle, D., eds) pp. 2371-2383, McGraw-Hill Inc., New York.
  • 41. Sverko V, Sobocanec S, Balog T, Marotti T. Age and gender differences in antioxidant enzyme activity: potential relationship to liver carcinogenesis in male mice. Biogerontology. 2004;5(4):235-42.
  • 42. Harman D. Aging: a theory based on free radical and radiation chemistry. J Gerontol 11: 298-300, 1956.
  • 43. Howes, R. M. © 2004. U.T.O.P.I.A. - Unified Theory of Oxygen Participation in Aerobiosis. Free Radical Publishing Co. Kentwood, LA.
  • 44. Howes, R.M. © 2005. The Medical and Scientific Significance of Oxygen Free Radical Metabolism. Free Radical Publishing Co. Kentwood, LA.
  • 45. Hydrogen Peroxide Monograph 1: Scientific, Medical and Biochemical Overview & Antioxidant Vitamins A, C, & E Monograph 2: Equivocal Scientific Studies, © 2006. Free Radical Publishing Co. Kentwood, LA.
  • 46. Cardiovascular Disease and Oxygen Free Radical Mythology. © 2006. Free Radical Publishing Co. Kentwood, LA.
  • 47. Diabetes and Oxygen Free Radical Sophistry. © 2006. Free Radical Publishing Co. Kentwood, LA.
  • 48. Harman, D., 1981. The aging process. Proc. Natl Acad. Sci. USA 78, 7124-7128.
  • 49. Beckman, K.B., Ames, B.N., 1998. The free radical theory of aging matures. Physiol. Rev. 78, 547-581) (Finkel, T., Holbrook, N.J., 2000. Oxidants, oxidative stress and the biology of ageing. Nature 408, 239-247.
  • 50. Balaban, R.S., Nemoto, S., Finkel, T., 2005. Mitochondria, oxidants, and aging. Cell 120, 483-495.
  • 51. Pani, G., Bedogni, B., Colavitti, R., Anzevino, R., Borrello, S., Galeotti, T., 2001. Cell compartmentalization in redox signaling. IUBMB Life 52, 7-16.
  • 52. Soberman, R.J., 2003. The expanding network of redox signaling: new observations, complexities, and perspectives. J. Clin. Invest. 111, 571-574.
  • 53. Yusuf, S., G. Dagenais, J. Pogue, et al. 2000. Vitamin E supplementation and cardiovascular events in high risk patients: The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 342:154-160.
  • 54. Dietary supplement with n-3 polyunsaturated acids and vitamin E after myocardial infarction: results of the GISSI-Prevention trial. Gruppo, Italiano per lo Studio Sopravvivenza nell'Infarto miocardico. 1999. Lancet. 354: 447-455.
  • 55. Heinonen, O.P., J.K. Huttunen, D. Albanes & ATBC cancer prevention study group. 1994. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N. Engl. J. Med. 330:1029-1035.
  • 56. Hennekens, C.H., J.E. Buring, J.E. Manson, et al. 1996. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N. Engl. J. Med. 334(18):1145-1149.
  • 57. Omenn, G.S., G.E. Goodman, M.D. Thornquist, et al. 1996. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N. Engl. J. Med. 334(18):1150-1155.
  • 58. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, Dowdy AA, Marino EK, Bolson EL, Alaupovic P, Frohlich J, and Albers JJ. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345: 1583-1592, 2001.
  • 59. Collins, R., J. Armitage, S. Parish, P. Sleight & R. Peto. 2002. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: A randomized placebo-controlled trial. Lancet. 360(9326):23-33.
  • 60. Vivekananthan, D.P., et al. 2003. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomized trials. Lancet. 361:2017-2023.
  • 61. Miller, E.R., R. Pastor-Barriuso, D. Dalal, et al. 2005. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann. Intern. Med. 142(1):37-46.
  • 62. Lichtenstein, A.H. & R.M. Russell. 2005. Essential nutrients: Food or supplements? JAMA. 294:351-358.
  • 63. Thompson, C.B. (1995) Science 267: 1456-1460.
  • 64. Albright, C. D., Salganik, R. I., Craciunescu, C. N., Mar, M. H. & Zeisel, S. H. (2003) Mitochondrial and microsomal derived reactive oxygen species mediate apoptosis induced by transforming growth factor-beta1 in immortalized rat hepatocytes. J. Cell Biochem. 89: 254-261.
  • 65. De Luca, L. M. & Ross, S. A. (1996) Beta-carotene increases lung cancer incidence in cigarette smokers. Nutr. Rev. 54: 178-180.
  • 66. Hampton, M.B., Fadeel, B., Orrenius, S. Redox regulation of the caspases during apoptosis. Ann. NY Acad. Sci. 1998. 854, 328-335.
  • 67. Jacobson, M.D. & Raff, M.C. Programmed cell death and Bcl-2 protection in very low oxygen. Nature 1995. 374, 814-816.
  • 68. P. Huang et al. Superoxide dismutase as a target for the selective killing of cancer cells. Nature. 2000 Sep 21;407(6802):390-5.
  • 69. Neil E. Kay, ROS: double-edged sword for leukemic cells (Mayo Clinic), Blood, 15 March 2006, Vol. 107, No 6, pp. 2212-2213.
  • 70. Chandra J, Hackbarth J, Le S, et al. Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells. Blood. 2003;102: 4512-4519.
  • 71. Shanafelt TD, Lee YK, Bone ND, et al. Adaphostin-induced apoptosis in CLL B cells is associated with induction of oxidative stress and exhibits synergy with fludarabine. Blood. 2005;105: 2099-2106.
  • 72. Mow BM, Chandra J, Svingen PA, et al. Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro. Blood. 2002;99: 664-671.
  • 73. Yi-He Ling, Leonard Liebes, Yiyu Zou and Roman Perez-Soler. Reactive Oxygen Species Generation and Mitochondrial Dysfunction in the Apoptotic Response to Bortezomib, a Novel Proteasome Inhibitor, in Human H460 Non-small Cell Lung Cancer Cells. J. Biol. Chem., Vol. 278, Issue 36, 33714-33723, September 5, 2003.
  • 74. Hileman EO, Liu J, Albitar M, Keating MJ, Huang P. Intrinsic oxidative stress in cancer cells: a biochemical basis for therapeutic selectivity. Cancer Chemother Pharmacol. 2004 Mar;53(3):209-19.
  • 75. S.Choi and S.V. Singh. Bax and Bak are required for apoptosis induction by sulforaphane, a cruciferous vegetable-derived cancer chemopreventive agent. Cancer Res. 2005 Mar 1;65(5):2035-43.
  • 76. S.V. Singh et al. Sulforaphane-induced cell death in human prostate cancer cells is initiated by reactive oxygen species. J Biol Chem. 2005 May 20;280(20):19911-24.
  • 77. Davies KJ. The broad spectrum of responses to oxidants in proliferating cells: a new paradigm for oxidative stress. IUBMB Life. 1999 Jul; 48(1):41-7.

 

Contact information:

Prof. Hon. Randolph M. Howes, M.D., Ph.D.

Adjunct Assistant Professor of Plastic Surgery, The Johns Hopkins Hospital, Baltimore, Md., U.S.A. and Espaldon Professor of Plastic and Reconstructive Surgery, University of Santo Tomas, Manila, Philippines.

Address for communication: 27439 Highway 441, Kentwood, Louisiana 70444-8152, USA. Email: rhowesmd@hughes.net




Information about this Article
Peer-review ratings (from 1 review, where a score of 100 represents the ‘average’ level):
Originality = 50.00, importance = 100.00, overall quality = 125.00
This Article was published on 26th February, 2007 at 02:19:14 and has been viewed 9119 times.

Creative Commons License
This work is licensed under a Creative Commons Attribution 2.5 License.
The full citation for this Article is:
Howes M.D., PhD., R. (2007). Cancer, Apoptosis and Reactive Oxygen Species: A New Paradigm. PHILICA.COM Article number 86.


<< Go back Review this ArticlePrinter-friendlyReport this Article


1 Peer review [reviewer #47336unconfirmed user] added 20th August, 2011 at 19:55:19

Although the main proposal made in the preprint appears reasonable, an adequate treatment of the problem requires a more precise approach that also includes Integrative Cancer Biology and Complex Systems biology modeling approaches that are currently available.

Recent preprints posted on Nature Proceeds address much more precisely the problem through adequate mathematical modeling of apoptosis in cancer and radical dose effects, etc., as well as other, relevant advanced technology/methodology aspects of this important problem of understanding Cancer, Apoptosis and Reactive Oxygen Species. However, this is not a *new* paradigm as claimed, because it has been around for at least ten years. What is a trully new paradigm —but not in this preprint— is an approach that allows personalized cancer therapy based on novel technologies linked with precise/ adequate mathematical modeling of apoptosis in cancer which is discussed only summarily and incompletely in this preprint. The cited list of references also falls far short from providing a strong, or sufficient basis for the conclusions drawn in the preprint. In spite of its flaws, this preprint is an improvement over the other 3 or 4 articles posted recently at Nature Proceeds on similar subjects.

Originality: 2, Importance: 4, Overall quality: 5




Website copyright © 2006-07 Philica; authors retain the rights to their work under this Creative Commons License and reviews are copyleft under the GNU free documentation license.
Using this site indicates acceptance of our Terms and Conditions.

This page was generated in 0.3246 seconds.